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BACKGROUND
Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves 
have been documented by four-dimensional computed tomography (CT). Whether 
anticoagulation can reduce these phenomena after transcatheter aortic-valve replace-
ment (TAVR) is not known.
METHODS
In a substudy of a large randomized trial, we randomly assigned patients who had under-
gone successful TAVR and who did not have an indication for long-term anticoagulation 
to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 
100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin 
[75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a 
mean (±SD) of 90±15 days after randomization. The primary end point was the percent-
age of patients with at least one prosthetic valve leaflet with grade 3 or higher motion 
reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed.
RESULTS
A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or 
higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could 
be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the anti-
platelet group (difference, −8.8 percentage points; 95% confidence interval [CI], −16.5 to 
−1.9; P = 0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) 
in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, 
−20.0 percentage points; 95% CI, −30.9 to −8.5). In the main trial, the risk of death or 
thromboembolic events and the risk of life-threatening, disabling, or major bleeding were 
higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively).
CONCLUSIONS
In a substudy of a trial involving patients without an indication for long-term anticoagu-
lation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy 
was more effective than an antiplatelet-based strategy in preventing subclinical leaflet-
motion abnormalities. However, in the main trial, the rivaroxaban-based strategy was 
associated with a higher risk of death or thromboembolic complications and a higher 
risk of bleeding than the antiplatelet-based strategy. (Funded by Bayer; GALILEO-4D 
ClinicalTrials.gov number, NCT02833948.)
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Leaflet Motion after Aortic-Valve Replacement
Transcatheter aortic-valve replace-ment (TAVR) for the treatment of severe aortic stenosis has become the standard 
of care for an increasing number of clinical 
indications on the basis of multiple large-scale 
randomized trials.1-7 Hypoattenuated leaflet thick-
ening and reduced leaflet motion, as detected by 
four-dimensional volume-rendered computed to-
mography (CT), have been reported in associa-
tion with both transcatheter and surgical aortic 
bioprosthetic valves.8,9 Several observational stud-
ies have alerted the medical community to these 
phenomena, have suggested a possible associa-
tion with an increased risk of ischemic cerebro-
vascular events, and have hinted at the possible 
usefulness of oral anticoagulation.8-17 However, 
data on this topic from randomized trials are 
lacking.
The oral direct factor Xa inhibitor rivaroxaban 
has been approved in several countries for the 
prevention of stroke in patients with atrial fibril-
lation and for the prevention and treatment of 
venous thromboembolism. The Global Study Com-
paring a Rivaroxaban-Based Antithrombotic Strat-
egy to an Antiplatelet-Based Strategy after Trans-
catheter Aortic Valve Replacement to Optimize 
Clinical Outcomes (GALILEO) was designed to 
investigate the effect of a treatment strategy that 
includes anticoagulation with rivaroxaban at a 
dose of 10 mg daily to reduce the risk of throm-
boembolic events after successful TAVR in pa-
tients who did not have an established indica-
tion for oral anticoagulation.18 GALILEO-4D was 
a dedicated substudy of the main GALILEO trial 
that aimed to evaluate the effect of a rivaroxa-
ban-based strategy as compared with an anti-
platelet-based antithrombotic strategy on leaflet 
thickening and leaflet-motion abnormalities in 
patients with transcatheter aortic bioprostheses.
Me thods
Trial Design
GALILEO-4D was designed as an investigator-
initiated, international, randomized, open-label, 
imaging substudy of the main GALILEO trial. 
The main trial was sponsored by Bayer in collabo-
ration with Janssen Pharmaceuticals. GALILEO-4D 
was separately sponsored by the European Car-
diovascular Research Institute (ECRI) with fund-
ing provided by Bayer. Bayer did not have any 
role in the design, conduct, analysis, or report-
ing of the results from the substudy.
The substudy was designed and executed un-
der the academic leadership of investigators at 
Rigshospitalet in Copenhagen, in collaboration 
with the ECRI. The substudy was conducted ac-
cording to its own protocol, which is available 
with the full text of this article at NEJM.org. The 
protocol was approved by the ethics committees 
and corresponding health authorities for all par-
ticipating sites. The substudy was conducted in 
compliance with the Declaration of Helsinki. De-
tailed information on roles and responsibilities 
is provided in the Supplementary Appendix, avail-
able at NEJM.org. The authors vouch for the ac-
curacy and completeness of the data and for the 
fidelity of the substudy to the protocol.
Patient Eligibility and Randomization
Men and women 18 years of age or older were 
eligible for participation in the GALILEO trial if 
they had undergone successful TAVR for aortic 
stenosis; detailed inclusion and exclusion criteria 
are provided in the Supplementary Appendix. 
Eligible patients who provided written informed 
consent were randomly assigned in a 1:1 ratio to 
either a rivaroxaban-based strategy or an anti-
platelet-based strategy.
The GALILEO-4D substudy enrolled patients 
at 12 sites that were involved in the main trial 
and that were able and willing to perform four-
dimensional CT after TAVR. All patients eligible 
for inclusion in the main trial were also candi-
dates for enrollment in the substudy, unless they 
had severe renal insufficiency (estimated glo-
merular filtration rate, <30 ml per minute per 
1.73 m2 of body-surface area), were undergoing 
dialysis, had post-TAVR unresolved acute kidney 
injury with renal dysfunction of stage 2 or higher, 
had iodine contrast allergy, or had another con-
dition that prohibited CT imaging. Written in-
formed consent, obtained at the same time as 
the consent for the main GALILEO trial, had to 
be obtained separately for participation in the 
substudy.
Treatment
Patients who were randomly assigned to the 
rivaroxaban-based strategy received rivaroxaban 
at a dose of 10 mg once daily plus aspirin at a 
dose of 75 to 100 mg once daily for 3 months, 
followed by monotherapy with rivaroxaban at a 
dose of 10 mg once daily. Patients who were 
randomly assigned to the antiplatelet-based 
strategy received aspirin at a dose of 75 to 100 mg 
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once daily and clopidogrel at a dose of 75 mg 
once daily for 3 months, followed by mono-
therapy with aspirin. More details regarding the 
treatment regimens are provided in the Supple-
mentary Appendix.
Imaging Studies
Patients included in GALILEO-4D were sched-
uled for a contrast-enhanced, electrocardiogram-
gated cardiac CT scan with full cardiac-cycle 
coverage (four-dimensional CT) and a transtho-
racic echocardiogram at the time of the 3-month 
follow-up visit (mean [±SD], 90±15 days after 
randomization). The four-dimensional CT acqui-
sition protocol is provided in the Supplementary 
Appendix. Depending on the scanner system and 
the institutional settings, the typical radiation 
exposure was 5 to 15 mSv. Leaflet thickening 
and motion were graded with the use of multi-
planar reformats, with additional volume-rendered 
assessment as needed. Leaflet motion was clas-
sified in five grades (0 to 4, with higher grades 
indicating more restricted motion).19 Four-dimen-
sional CT core laboratory evaluations were in-
dependently performed at St. Paul’s Hospital, 
Vancouver, British Columbia, and New York Uni-
versity Langone Health, New York, by investiga-
tors who were not aware of the patients’ identi-
ties, the transthoracic echocardiographic data, or 
the random treatment assignment.
To limit crossovers in the main GALILEO trial, 
the results of the four-dimensional CT scan were 
concealed from the treating physician and pa-
tient until the end of the main trial. In the event 
of an overt ischemic stroke or systemic embo-
lism, a clinically indicated cardiac four-dimen-
sional CT scan could be performed. The result of 
this scan could be made available to the treating 
physician.
End Points
All end points for the GALILEO-4D substudy were 
assessed at 90 days — at the time of perfor-
mance of the four-dimensional CT scan. The 
primary end point of the substudy was the per-
centage of patients with at least one prosthetic 
valve leaflet with reduced motion of grade 3 or 
higher (i.e., involving >50% of the leaflet). Sec-
ondary end points were the percentage of valve 
leaflets with reduced motion of grade 3 or higher, 
the percentage of patients with at least one 
thickened leaflet, the percentage of valve leaflets 
with thickening, the transprosthetic mean pres-
sure gradient as determined by transthoracic echo-
cardiography, and safety and efficacy end points 
identical to the primary end points of the main 
GALILEO trial. A full list of end points and 
definitions is provided in the Supplementary Ap-
pendix.
Statistical Analysis
The main GALILEO trial was an event-driven 
trial with a target of 440 primary end-point 
events (the primary end point was a composite 
of death from any cause or thromboembolic 
events) and an originally anticipated enrollment 
of 1520 patients. In a separate power calculation 
for the GALILEO-4D substudy, we assumed that 
the primary end point of reduced motion of at 
least grade 3 at 90 days would occur in 20% of 
patients in the antiplatelet group. It was esti-
mated that 246 patients would need to be enrolled 
to show a projected 65% lower percentage of 
patients with a primary end point in the rivaroxa-
ban group, with a loss to follow-up of 5 to 10%.
The main GALILEO trial was terminated on 
August 13, 2018, at the recommendation of the 
data and safety monitoring board because of 
safety concerns. This did not affect the treatment 
or follow-up of patients enrolled in GALILEO-4D, 
since the last patient had been enrolled in the 
substudy on May 23, 2018.
The primary and secondary end points were 
evaluated in the intention-to-treat and per-proto-
col populations; these populations are defined 
in Figure S1 and Table S1 in the Supplementary 
Appendix. Unadjusted 95% confidence intervals 
for the differences in percentages between the 
two treatment groups are reported20; these un-
adjusted intervals cannot be used to infer effects. 
The Fisher’s exact probability test was used to 
compare the percentages of patients with the 
primary end point between the treatment groups. 
Since no correction for multiple comparisons 
was used, the results of analyses other than that 
of the primary end point should be interpreted 
with caution. All statistical analyses were per-
formed with SPSS software, version 24.0 (IBM).
R esult s
Patient Population
A sample of 246 patients was planned for the 
substudy on the basis of the power calculation. 
In May 2018, after 231 patients had been en-
rolled, the European Union General Data Protec-
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tion Regulation became effective, which would 
have required revision and reapproval of the 
consent forms that were then in use. Since re-
cruitment was already close to the target num-
ber, the decision was made to close enrollment 
in the substudy.
Among the 231 patients enrolled, 115 were 
assigned to the rivaroxaban group and 116 to 
the antiplatelet group. Figure 1 shows the num-
ber of four-dimensional CT scans that were avail-
able and of sufficient image quality to allow 
assessment of both leaflet thickening and mo-
tion abnormalities in the intention-to-treat popu-
lation; Figure S2 provides the same information 
for the per-protocol population. The characteris-
tics of the patients in the substudy were well 
balanced between the treatment groups (Table 1 
and Table S2A) and were similar to those in the 
main GALILEO population, except that only a 
few high-risk patients were enrolled in the sub-
study (Table S2B).
Primary End Point
In the intention-to-treat analysis, 2 of the 97 pa-
tients (2.1%) with scans that could be evaluated 
in the rivaroxaban group had at least one valve 
leaflet with reduced motion of grade 3 or higher, 
as compared with 11 of 101 (10.9%) in the anti-
platelet group (between-group difference, −8.8 
percentage points; 95% confidence interval [CI], 
−16.5 to −1.9; P = 0.01) (Table 2 and Fig. 2). In the 
per-protocol analysis, the number of patients 
who had at least one valve leaflet with reduced 
motion of grade 3 or higher was 0 in the rivarox-
aban group and 9 (9.6%) in the antiplatelet group 
(Table S3).
Secondary End Points of Four-Dimensional 
CT Imaging
In the intention-to-treat analysis, hypoattenuat-
ed thickening of at least one leaflet was found 
in 12 of 97 patients (12.4%) who were random-
ly assigned to the rivaroxaban group, as com-
pared with 33 of 102 patients (32.4%) who were 
randomly assigned to the antiplatelet group 
(between-group difference, −20.0 percentage 
points; 95% CI, −30.9 to −8.5) (Table 2 and 
Fig. 2). Consistent results were obtained in the 
per-protocol analysis and in the analysis at the 
leaflet level, with the number of leaflets used 
Figure 1. Population and Four-Dimensional CT Scans.
Shown are the numbers of four-dimensional computed tomographic (CT) scans that were available and of sufficient 
image quality to evaluate leaflet thickening and motion in each treatment group in the intention-to-treat population. 
One patient with a major clinical event (an episode of life-threatening bleeding) did not undergo scanning. The most 
common reasons for not undergoing scanning were logistic constraints, renal dysfunction, and patient preference. 
However, a systematic record of the reasons for 21 patients not undergoing scanning was not obtained in this substudy.
231 Patients underwent randomization
115 Were assigned to the rivaroxaban group 116 Were assigned to the antiplatelet group
16 Were excluded
3 Died at <90 days
13 Were not scanned
10 Were excluded
2 Died at <90 days
8 Were not scanned
2 Had scans
that could not
be evaluated
2 Had scans
that could not
be evaluated
4 Had scans
that could not
be evaluated
5 Had scans
that could not
be evaluated
97 Had scans that could
be evaluated for leaflet
thickening
102 Had scans that could
be evaluated for leaflet
thickening
97 Had scans that could
be evaluated for leaflet
motion
101 Had scans that could
be evaluated for leaflet
motion
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Characteristic
Rivaroxaban 
(N = 115)
Antiplatelet 
(N = 116)
Clinical characteristics
Age — yr 79.7±7.3 80.5±6.2
Male sex — no. (%) 74 (64.3) 74 (63.8)
Body-mass index† 27.7±6.5 27.8±5.1
Hypertension — no. (%) 98 (85.2) 95 (81.9)
Diabetes mellitus — no. (%) 21 (18.3) 27 (23.3)
STS risk score — %‡ 2.8±1.5 3.0±2.1
STS risk category — no. (%)‡
High 1 (0.9) 3 (2.6)
Intermediate 37 (32.2) 35 (30.2)
Low 77 (67.0) 78 (67.2)
Congestive heart failure — no. (%) 52 (45.2) 52 (44.8)
Coronary artery disease — no. (%)§ 42 (36.5) 36 (31.0)
Previous stroke — no. (%) 11 (9.6) 6 (5.2)
Peripheral artery disease — no. (%) 10 (8.7) 10 (8.6)
Previous venous thromboembolism — no. (%) 1 (0.9) 1 (0.9)
Permanent pacemaker — no. (%) 14 (12.2) 14 (12.1)
Chronic obstructive pulmonary disease — no. (%) 19 (16.5) 16 (13.8)
Glomerular filtration rate — ml/min/1.73 m2 73.6±19.2 76.6±19.4
Procedural characteristics
Valve type — no. (%)
Balloon-expandable 52 (45.2) 54 (46.6)
Self-expandable 63 (54.8) 62 (53.4)
Supra-annular leaflet position 37 (32.2) 46 (39.7)
Valve-in-valve — no. (%) 3 (2.6) 1 (0.9)
Post-TAVR echocardiographic characteristics before hospital discharge
Aortic-valve area — cm2 1.8±0.5 1.8±0.5
Mean aortic-valve gradient — mm Hg 11±5 11±4
Left ventricular ejection fraction — % 55±11 56±10
Paravalvular aortic regurgitation — no. (%)
None or trace 94 (81.7) 96 (82.8)
Mild 19 (16.5) 19 (16.4)
Moderate or severe 2 (1.7) 1 (0.9)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. TAVR denotes transcatheter 
aortic-valve replacement.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  The risk model of the Society of Thoracic Surgeons (STS) uses an algorithm that is based on the presence of coexisting 
illnesses to predict 30-day operative mortality. The STS score equals the predicted mortality expressed as a percentage. 
A score of greater than 8% indicates high risk, 3 to 8% intermediate risk, and less than 3% low risk.
§  Coronary artery disease is defined as previous myocardial infarction, percutaneous coronary intervention, or coronary-
artery bypass grafting.
Table 1. Baseline Characteristics of the Patents in the Intention-to-Treat Population.*
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as the denominator. All available four-dimen-
sional CT data analyses are reported in Tables 
S3 and S4.
Echocardiographic Findings
There was no significant difference between the 
treatment groups with respect to the various 
End Point Rivaroxaban Antiplatelet
Difference in Percentage 
(95% CI)
no./total no. (%) percentage points
Four-dimensional CT end points
Reduced leaflet motion†
Patient level
At least one leaflet with grade ≥3 reduced motion‡ 2/97 (2.1) 11/101 (10.9) −8.8 (−16.5 to − 1.9)
At least one leaflet with grade ≥2 reduced motion 4/97 (4.1) 21/101 (20.8) −16.7 (−25.9 to −7.6)
At least one leaflet with grade ≥1 reduced motion 12/97 (12.4) 32/101 (31.7) −19.3 (−30.2 to −7.8)
Leaflet level
Leaflets with grade ≥3 reduced motion 3/291 (1.0) 14/303 (4.6) −3.6 (−6.7 to −0.9)
Leaflets with grade ≥2 reduced motion 6/291 (2.1) 26/303 (8.6) −6.5 (−10.4 to −3.0)
Leaflets with grade ≥1 reduced motion 16/291 (5.5) 51/303 (16.8) −11.3 (−16.4 to −6.3)
Severity of reduced leaflet motion
Grade 1 10/291 (3.4) 25/303 (8.3) −4.9 (−8.8 to −1.0)
Grade 2 3/291 (1.0) 12/303 (4.0) −3.0 (−5.8 to −0.4)
Grade 3 3/291 (1.0) 12/303 (4.0) −3.0 (−5.8 to −0.4)
Grade 4 0 2/303 (0.7) −0.7 (−2.4 to 0.7)
Leaflet thickening
Patient level
At least one thickened leaflet 12/97 (12.4) 33/102 (32.4) −20.0 (−30.9 to −8.5)
At least two thickened leaflets 3/97 (3.1) 16/102 (15.7) −12.6 (−21.1 to −4.5)
At least three thickened leaflets 1/97 (1.0) 4/102 (3.9) −2.9 (−8.7 to 2.3)
Leaflet level
Leaflets with thickening 16/291 (5.5) 53/306 (17.3) −11.8 (−16.9 to −6.8)
Clinical end points at time of four-dimensional CT scan§
Major or life-threatening bleeding 4/115 (3.5) 1/116 (0.9) —
Thromboembolic event 4/115 (3.5) 2/116 (1.7) —
Nondisabling stroke 1/115 (0.9) 0 —
Disabling stroke 3/115 (2.6) 2/116 (1.7) —
Death 3/115 (2.6) 2/116 (1.7) —
*  Analyses were not corrected for multiple comparisons.
†  Leaflet motion was assigned a grade from 0 to 4: grade 0 denotes unrestricted, grade 1 minimally restricted (with restriction limited to the 
base), grade 2 mildly restricted (involving more than the base but <50% of the leaflet), grade 3 moderately restricted (involving >50% but 
<75% of the leaflet), and grade 4 largely immobile.
‡  This end point was the primary end point of the substudy. In case of discrepancies between the core laboratories (9 of 198 cases, 4.5%),  
a third independent expert was consulted to reach a consensus.
§  Clinical end points were adjudicated according to the Valve Academic Research Consortium–2 definitions.
Table 2. Outcomes in the Intention-to-Treat Population.*
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Figure 2. Four-Dimensional CT Imaging End Points.
Panel A shows the different degrees of hypoattenuated leaflet thickening and reduced leaflet motion used in classi-
fying the findings on four-dimensional CT and provides definitions of the different degrees of reduced leaflet mo-
tion. Panel B shows the percentages of patients who had at least one prosthetic valve leaflet with reduced motion 
of grade 3 or higher and any degree of leaflet thickening in the rivaroxaban group and the antiplatelet group in the 
intention-to-treat analysis. The two-sided P value from the Fisher’s exact probability test for the comparison of the 
primary end point between the two treatment groups is shown. Hypoattenuated leaflet thickening was defined as 
visually identifiable increased leaflet thickness on contrast-enhanced multiplanar reformats, carefully aligned with 
the long and short axes of the valve prosthesis.19
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Reduced leaflet motion was defined as
• Grade 0: normal or unrestricted
• Grade 1: minimally restricted — limited to base
• Grade 2: mildly restricted — involving more than the base
but <50% of the leaflet along curvilinear dimension
• Grade 3: moderately restricted — involving >50%
but <75% of the leaflet along curvilinear dimension
• Grade 4: largely immobile
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echocardiographic measures. An increase in the 
mean valve gradient of 5 mm Hg or more was 
found in 11 patients (7.3%) who did not have 
leaflet thickening and in 7 patients (15.9%) who 
did have leaflet thickening. A similar increase in 
the mean valve gradient was found in 14 patients 
(7.7%) who did not have reduced leaflet motion 
of grade 3 or higher and in 4 patients (30.8%) 
who did have reduced leaflet motion of grade 3 
or higher (Tables S5 and S6).
Moderate hemodynamic structural valve dete-
rioration21 was reported in 4 of 207 patients 
(1.9%) at the time of the 3-month follow-up 
visit (Table S7). Two patients had an increase in 
the mean valve gradient of at least 10 mm Hg 
from baseline; one of these patients had clinical 
valve thrombosis with reduced leaflet motion of 
grade 3 or higher and heart failure symptoms.
Clinical Events
The percentages of patients in the substudy who 
had major bleeding, thromboembolic events, or 
death at 90 days were each less than 3%, and 
only three patients with reported stroke under-
went cardiac four-dimensional CT scanning; 
this did not allow for further statistical analysis 
(Tables S8 and S9).
Discussion
In the GALILEO trial, a rivaroxaban-based strat-
egy was compared with an antiplatelet-based 
strategy for the prevention of clinical thrombo-
embolic events after TAVR. The GALILEO-4D 
substudy used four-dimensional CT imaging at 
90 days after randomization to evaluate a sub-
group of the bioprosthetic aortic valves that were 
implanted during the trial. The main findings 
were as follows: the overall percentages of pa-
tients with significantly reduced leaflet motion 
(grade 3 or higher) and leaflet thickening were 
6.6% and 22.6%, respectively; both findings were 
less frequent with the rivaroxaban-based strate-
gy than with the antiplatelet-based strategy, and 
echocardiography was not useful in identifying 
patients with these valvular abnormalities.
Subclinical leaflet thickening and reduced 
leaflet motion have been described with vari-
able frequency in both transcatheter and surgi-
cal aortic bioprostheses.8,9 Reports on the inci-
dence of leaflet thickening mainly range between 
7% and 15% but have reached 38% in some 
studies.8-17,22,23 Our findings are not necessarily 
representative of an unselected population of 
patients who have undergone TAVR, since pa-
tients with known atrial fibrillation or an indi-
cation for oral anticoagulation (30 to 40% of all 
patients who undergo TAVR) were excluded from 
the substudy, half our patients were randomly 
assigned to rivaroxaban (10 mg daily), and pa-
tients were enrolled only after a successful TAVR 
procedure.
Previous observational studies indicated that 
oral anticoagulation reduces the risk of leaflet 
thickening more effectively than antiplatelet 
therapy.8-17 In addition, there are registry data 
suggesting that dual antiplatelet therapy — 
which is the current standard of care after TAVR 
for patients without an established indication for 
oral anticoagulation24,25 — is not superior to 
single-agent antiplatelet therapy for the preven-
tion of this phenomenon.9 However, in these 
registries, treatment was not randomly assigned, 
with resulting inherent patient selection bias, 
and the registries reported on a variety of differ-
ent antithrombotic agents, dosages, and combi-
nations.
In this randomized clinical trial, the percent-
ages of patients with reduced leaflet motion and 
leaflet thickening were shown to be lower in the 
group assigned to a treatment strategy including 
anticoagulation with rivaroxaban at a dose of 
10 mg once daily than in the group assigned to 
a treatment strategy involving antiplatelet therapy. 
Despite this beneficial effect of anticoagulation 
on the four-dimensional CT imaging findings, 
in the main GALILEO trial (also now published 
in the Journal) the rivaroxaban-based antithrom-
botic strategy was associated with a higher risk 
of death or thromboembolic complications (haz-
ard ratio, 1.35) and a higher risk of life-threat-
ening, disabling, or major bleeding (hazard ratio, 
1.50) than the antiplatelet-based strategy.26 There 
were too few clinical events in the imaging sub-
study to permit any assessment of the effect of 
reduced leaflet motion and leaflet thickening on 
clinical outcomes. The unsuitability of transtho-
racic echocardiography for the detection of sub-
clinical leaflet thrombosis has previously been 
reported8-15 and was reconfirmed here.
Limitations of this substudy include its sam-
ple size, which was too small to allow for ade-
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quate correlation of imaging findings with clini-
cal events; the fact that imaging was performed 
at only one time point (since these phenomena 
have been reported to be dynamic processes)14,15; 
the lack of valve imaging after cessation of anti-
coagulant therapy; and the lack of cerebrovascu-
lar imaging. Different antithrombotic agents or 
different doses would probably have different 
levels of risk and benefit; we selected a regimen 
without extensive previous data for guidance. 
Finally, we did not study the long-term effect on 
valve durability.
In conclusion, in patients without an estab-
lished indication for long-term anticoagulation 
after successful TAVR, a treatment strategy that 
included anticoagulation with rivaroxaban at a 
dose of 10 mg once daily was more effective 
than an antiplatelet-based strategy in prevent-
ing subclinical reduced leaflet motion at 90 days. 
However, we cannot recommend routine imaging 
for the detection of reduced leaflet motion or the 
routine use of anticoagulation after TAVR with 
the aim of preventing leaflet-motion abnor-
malities, given the unfavorable clinical outcomes 
with rivaroxaban in the main GALILEO trial.
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